Nanoparticle Gel System Delivers Liraglutide Directly to Gums for Diabetic Gum Disease | Research

The takeaway

A PLGA/HA sustained-release system loaded with liraglutide effectively treated diabetic periodontitis in rats by providing local drug delivery and inhibiting necroptosis-driven tissue destruction.

Dual-action local therapy
Liraglutide nanoparticle scaffold addresses both diabetic glycemic control and periodontal tissue destruction

What the researchers found

PLGA/HA nanoparticles loaded with liraglutide provided sustained local release that reduced diabetic periodontitis severity by inhibiting necroptosis in periodontal tissues, addressing both glycemic control and local tissue destruction.

Why it matters

Diabetic periodontitis is a common complication where systemic diabetes worsens local gum disease, and vice versa. Local delivery of a GLP-1 drug addresses both problems simultaneously — controlling blood sugar locally while reducing the inflammatory destruction of gum tissue.

The numbers in context

PLGA nanoparticles (30,000 Da) had 86.2% encapsulation efficiency and 4.3% drug loading. Cumulative liraglutide release reached about 60% after 8 days. Tested in diabetic rat periodontitis model.

How the study worked

Animal study in diabetic rats with periodontitis. Developed and characterized PLGA nanoparticles loaded with liraglutide in a HA scaffold. Assessed particle morphology, size, drug release kinetics, and in vivo efficacy on periodontal inflammation and bone loss.

Who was studied

Diabetic rats with experimentally induced periodontitis

What this study cannot tell us

Animal study in rats — dental anatomy and disease progression differ from humans; long-term stability and degradation of the HA/PLGA system in the oral environment needs assessment; comparison with standard periodontal treatments not performed; scale-up for clinical use unaddressed.

How to read the evidence

Preclinical animal study demonstrating proof-of-concept. Novel application of an existing peptide drug in a new delivery format and indication.

When this study was published

Published in 2025, extending liraglutide research into the dental/periodontal field.

The bigger picture

This illustrates the growing potential of peptide drugs beyond their primary indications. Liraglutide was designed for systemic diabetes management, but local delivery to specific tissues could unlock entirely new therapeutic applications, from dental to wound healing.

Questions still open

Could this local delivery approach be applied at dental clinics during routine periodontal procedures?
How long does a single application of the liraglutide-loaded scaffold provide therapeutic benefit?
Would other GLP-1 drugs work equally well in this delivery system?

Common questions

How are diabetes and gum disease connected?

Diabetes and periodontitis have a two-way relationship: high blood sugar promotes bacteria that cause gum disease, while gum inflammation makes blood sugar harder to control. Treating one helps the other, which is why a dual-action approach targeting both is so appealing.

How would this treatment be applied in a dental office?

The liraglutide-loaded nanoparticle scaffold would be placed directly at the affected gum and bone site during a dental procedure. It would then slowly release the drug over time, providing continuous treatment without daily injections or pills.

Read the original research

PLGA/HA sustained-release system loaded with liraglutide for the treatment of diabetic periodontitis through inhibition of necroptosis.

Materials today. Bio, 31, 101582

View on PubMed ↗Publisher’s paper ↗

Citation

Pang, Yunqing; Kong, Lingyuan; Li, Yuanyuan; Li, Jiamin; Ma, Qianlong; Qiu, Jing; Wang, Jing. (2025). PLGA/HA sustained-release system loaded with liraglutide for the treatment of diabetic periodontitis through inhibition of necroptosis.. Materials today. Bio, 31, 101582. https://doi.org/10.1016/j.mtbio.2025.101582